REVIEW ARTICLE

The influence of pain, agitation, and their management on the immature brain

Christopher McPherson1,2, Steven P. Miller3, Mohamed El-Dib4, An N. Massaro5 and Terrie E. Inder4

Preterm infants are exposed to frequent painful procedures and agitating stimuli over the many weeks of their hospitalization in the neonatal intensive care unit (NICU). The adverse neurobiological impact of pain and stress in the preterm infant has been well documented, including neuroimaging and neurobehavioral outcomes. Although many tools have been validated to assess acute pain, few methods are available to assess chronic pain or agitation (a clinical manifestation of neonatal stress). Both nonpharmacologic and pharmacologic approaches are used to reduce the negative impact of pain and agitation in the preterm infant, with concerns emerging over the adverse effects of analgesia and sedatives. Considering benefits and risks of available treatments, units must develop a stepwise algorithm to prevent, assess, and treat pain. Nonpharmacologic interventions should be consistently utilized prior to mild to moderately painful procedures. Sucrose may be utilized judiciously as an adjunctive therapy for minor painful procedures. Rapidly acting opioids (fentanyl or remifentanil) form the backbone of analgesia for moderately painful procedures. Chronic sedation during invasive mechanical ventilation represents an ongoing challenge; appropriate containment and an optimal environment should be standard; when indicated, low-dose morphine infusion may be utilized cautiously and dexmedetomidine infusion may be considered as an emerging adjunct.

Pediatric Research (2020) 88:168–175; https://doi.org/10.1038/s41390-019-0744-6

INTRODUCTION

The rate of preterm birth is rising around the world. Improved neonatal intensive care has reduced the mortality and increased the survival of preterm infants. Despite advances in neonatal intensive care, preterm birth remains a leading cause of neurodevelopmental disability.1 Neurodevelopmental challenges in infants born preterm often follow severe intraventricular hemorrhage (IVH) and white matter injury (WMI).2-4 More recent studies are shifting the paradigm of brain injury in the preterm infant from a “one-hit brain injury” to overall alteration in trajectory of brain maturation.5 An important modifiable factor that has been gaining interest in the clinical and research setting is pain in the neonatal intensive care unit (NICU).

In April 2019, an expert panel met at the annual Neonatal Neurocritical Care Special Interest Group (www.NNCC-SIG.org) meeting to review approaches to measuring and managing pain in the NICU. In this article, the panel will review the topic in detail, addressing factors related to (a) the link between pain and aberrant maturation in the developing brain; (b) methods to assess pain in the NICU; (c) nonpharmacologic and pharmacologic management of pain and agitation in preterm infants; and (d) knowledge gaps and future research directions.

HISTORICAL PERSPECTIVE ON PRETERM PAIN

As recently as 30 years ago, preterm infants underwent major surgical procedures without perioperative or postoperative analgesia.6 The traditional definition of pain relying on self-reported perception and emotional experience presents challenges in non-verbal populations, including but not limited to preterm infants.7 Careful investigation, including basic science and clinical research, documented the unique susceptibility of preterm infants to adverse metabolic, behavioral, and clinical responses to acute pain, sparking a revolution in pain science in the neonatal intensive care.7-9 Ascending pathways mediating nociception connect peripheral sensory neurons to the thalamus between 20 and 24 weeks of gestation, while descending inhibitory pathways mature beyond term gestation.10 In fact, preterm infants have lower flexor reflex thresholds and poor localization and discrimination of sensory input, leading to increased hormonal and physiologic responses to painful stimuli compared to older patients.10,11 After tissue damage, preterm infants experience prolonged hyperalgesia and allodynia, leading to chronic periods of nociception and stress.12

In the modern era, provision of analgesia prior to major procedures ranging from endotracheal intubation to invasive surgery represents standard neonatal care.13 However, investigation of the relative short- and long-term safety of newer analgesic and anesthetic agents challenges investigators and clinicians.14,15 Nonpharmacologic comfort measures have also been widely implemented for minor procedural pain; however, the optimal bundle of interventions remains undefined due to gaps in available evidence.16 At the confluence of nonpharmacologic and pharmacologic therapy, sucrose continues to require careful investigation despite decades of widespread utilization.17 Finally,
the optimal approach to preterm infants experiencing chronic agitation, most commonly from invasive mechanical ventilation, perplexes both clinicians and investigators.18

**IMPACT OF PAIN ON NEURODEVELOPMENT IN THE PRETERM INFANT**

Patterns of injury in the immature brain, such as WMI, result from vulnerability of specific cell populations during certain times in development.5,17 WMI is seen in ~1/3 of very preterm infants as a specific pattern of injury on clinical magnetic resonance imaging (MRI), reflecting these selective cell vulnerabilities.4,20 In the preterm brain, early lineage oligodendroglia are vulnerable to insults that do not impact mature myelin-forming oligodendrocytes. Buser et al.21 identified how the primary mechanism of myelination failure in the preterm infant involves dysmaturation, a disrupted cellular response whereby pre-oligodendrocytes fail to differentiate in diffuse astrogliotic lesions (i.e., pre-oligodendrocyte maturation arrest). Dysmaturation of neuronal structures was then identified in experimental and clinical imaging studies.5,22–27 Brain dysmaturation, including that measured in the white matter and in the gray matter, is the most important predictor of the high burden of neurodevelopmental impairments in preterm infants. Potentially modifiable neonatal predictors of brain dysmaturation and neurodevelopmental disabilities in this population include sepsis, retinopathy of prematurity, and chronic lung disease.6,25

With advances in neonatal intensive care and reductions in the burdens of the major morbidities that impact infants born preterm, “everyday” clinical exposures are now also recognized as key predictors of brain maturation in preterm infants. Pain is one such “everyday” clinical exposure. Increasing evidence suggests that pain is a central factor that predicts dysmaturation, especially in babies born very preterm and in those with many early exposures to pain. Preterm infants often spend months in the NICU, where they receive many painful procedures that are essential to lifesaving care. Preterm infants exposed to more procedural pain demonstrated reduced white matter and corticospinal tract fractional anisotropy (FA) as well as lower N-acetyl-aspartate/choline in subcortical gray matter, even when comprehensively accounting for neonatal illness severity and exposure to sedatives and analgesics.28,29 Importantly, the changes in white matter FA relate to changes in diffusivity aligned along the long axis of neurons in contrast to the changes in FA related to infection and mechanical ventilation, which are perpendicular to the axonal component of diffusion. These findings further bolster the independent association of procedural pain with brain dysmaturation. The observations related to procedural pain are also congruent with studies of neonatal stress. Greater neonatal stress predicts decreased frontal and parietal brain width and altered diffusion and functional connectivity in the temporal lobes.30 More recent observations demonstrate that greater procedural pain, especially in early life, is associated with smaller thalamic volumes, specifically in the somatosensory thalamus, and poor functional outcomes to 3 years of age (Fig. 1).25

Pain in neonatal life has a long-term impact on the developing brain. In a cohort of preterm infants studied at 8 years of age, greater exposure to neonatal pain predicted thinner cortex in multiple brain regions, predominantly in the frontal and parietal lobes.31 In other studies of this cohort, greater exposure to pain is also associated with smaller regional volumes in the limbic system and basal ganglia at 8 years of age.32 The association of pain with lower FA in superior white matter persists to school age, and associates with IQ.33 Furthermore, cumulative neonatal pain-related stress is also related to brain function as reflected in changes to background cortical rhythmicity at school age, which negatively predicts visual–perceptual abilities.34

Pain also intersects with other common neonatal morbidities and may be modified by patient-specific factors. For example, infants with infections are exposed to more painful procedures, and these painful procedures predict poor somatic growth and brain maturation in preterm infants from early life to term age.25,28,35 Recent studies highlight that the relationship between pain and brain morphology is modulated by genes known to impact pain sensitivity, neuronal survival, and synaptic plasticity.32

**ASSESSMENT OF PAIN AND AGITATION IN THE PRETERM INFANT**

A structured systematic manner to evaluate neonatal pain and agitation during hospital stays is of great importance in order to...
target strategies to prevent short- and long-term consequences. The most commonly used assessment tools are clinical pain scoring systems. In using these clinical scoring systems to assess pain and agitation, it is first important to define the circumstances that the assessment is designed to capture. For the current neonatal pain assessment tools that will be outlined more fully below, the tools are designed to characterize responses to acute pain, such as postoperative pain, procedural pain, or acute agitation associated with handling. They were not created to characterize chronic pain or agitation associated with either chronic noxious experiences and/or deprivation of positive or nurturing experiences.

All neonatal pain assessment tools are comprised of one or several observable indicators:

- Physiological (e.g., heart rate, blood pressure, respiration rate, oxygen saturation)—objective, but may be influenced by factors other than pain or agitation.
- Behavioral (e.g., crying, facial expression, bodily reactions, calming down, skin color)—subjective; facial grimacing specific for pain but cry and bodily reactions may lack sensitivity. Some such as “calming down” are not well operationalized.
- Contextual (e.g., gestational age, awake/asleep)—objective, affect physiological and behavioral responses to painful stimuli, but do not indicate the presence of pain.

The five most commonly used neonatal assessment tools are outlined in Table 1. They include the Neonatal Facial Coding System-Revised,36 Premature Infant Pain Profile-Revised,37 Neonatal Pain, Agitation and Sedation Scale,38 Neonatal Infant Pain Scale,39 and Bernese Pain Scale Neonates.40 These five scales were recently compared in 42 term and preterm infants who were predominantly >34 weeks gestational age in the setting of a painful procedure (venipuncture) and a stressful procedure (diaper change). Inter-rater reliability was very high (intraclass coefficients >0.96) with notably lowest internal consistency for stressful procedures.41 The highest consistency was obtained on the NFCS-R. It did appear that standard physiological measures were not as consistently expressed as measures of pain in comparison to behavioral measures. It also appeared that behavioral measures of body tenseness and movement were more often reliably affected by pain than facial grimacing. The authors concluded that this study confirmed that psychometrically sound assessment tools exist for evaluation of newborn pain and that focus should shift to training, clinical utility, and an understanding of the appropriate management related to the scores.

While observational scoring systems represent the standard of pain assessment in clinical care, investigators have explored additional measures of pain or agitation. These have included electroencephalography, which has been shown to discriminate noxious painful stimuli from touch with the highest specificity.42,43 Near-infrared spectroscopy (NIRS) has also been shown to detect noxious cortical activation from painful stimuli with oxygenated hemoglobin showing pain-associated increases in the contralateral somatosensory cortex.44,45 Skin conductance has also been proposed as a tool for the measurement of autonomic function reflecting pain or stress.46 Finally, salivary cortisol has been shown to increase after a painful or stressful experience in preterm and term born infants.47

A recent study compared measurements from NIRS, foot skin conductance, and salivary cortisol alongside the NFCS for pain evaluation in 113 3-day-old term born infants who underwent a single venipuncture. Given that all measures only mildly or moderately correlated with the NFCS, the authors concluded that the measures appeared to reflect differential physiological responses to pain with the NIRS, heart rate, and oxygen saturations representing an acute response to pain, while the skin conductance and salivary cortisol represented a more prolonged stressful response to pain.48 This differential time course of physiologic response to pain may reflect differing neurological impact. Another review article recently summarized non-invasive monitoring of stress biomarkers in the newborn period and found that the most commonly used marker remained as cortisol in saliva (reflecting acute stress) or hair (reflecting chronic stress).49 Further research is urgently needed to determine the optimal measures of acute and chronic pain and stress in infancy.

**NONPHARMACOLOGIC TREATMENT OF PAIN AND AGITATION**

The clear short- and long-term adverse effects of untreated pain and agitation in preterm infants require a multimodal approach, including both nonpharmacologic and pharmacologic strategies. Nonpharmacologic strategies with potential benefit prior to minor painful procedures include non-nutritive sucking, breast milk, music therapy, skin-to-skin contact, kangaroo care, and facilitated tucking.16 These interventions consistently reduce behavioral responses to minor acute painful procedures, such as needle sticks. Uniquely, facilitated tucking improves both pain reactivity (immediately after the painful stimulus) and immediate regulation (at least 30 s after the painful stimulus) in preterm infants.40 Unfortunately, despite over 70 randomized controlled trials including over 7000 infants and young children, low-quality evidence pervades this field of study, potentially contributing to underutilization of these interventions in clinical practice.51 Trials generally include small samples, with few examining identical combinations of painful procedure, intervention, and assessment

| Tool | Score | Reliability |
|------|-------|-------------|
| Neonatal Facial Coding System-Revised (NFCS-R) | Five domains of facial movement | 0–5 | High inter-rater and construct validity |
| Premature Infant Pain Profile-Revised (PIPP-R) | Two physiological, three behavioral two contextual items | 0–18 | Moderate consistency, Good validity |
| Neonatal Pain, Agitation and Sedation Scale (N-PASS) | Five items: (1) crying; (2) behavior state; (3) facial expression; (4) tone of extremities; (5) vital sign changes (choice between HR, blood pressure, pulse, and oxygen saturation) | 0–13 for preterm, 0–10 for term | High consistency, High validity, Treatment recommended with score >3 |
| Neonatal Infant Pain Scale (NIPS) | Six behavioral indicators | 0–7 | High consistency, Limited validity data |
| Bernese Pain Scale Neonates (BPSN) | Three physiological and six behavioral indicators | 0–27 | High consistency, High validity |
technique. These limitations prohibit any conclusions regarding the optimal nonpharmacologic bundle of care for preterm infants. The confluence of low-quality evidence for existing interventions and the ethical principles governing randomized controlled trials involving painful procedures creates a challenging environment for researchers.\textsuperscript{12} Leveraging unique trial designs, such as non-inferiority trials, and broadening assessed outcomes to include both subjective and objective measurements of infant response hold the promise of expanding knowledge in this area of study without causing unnecessary pain and stress to fragile patients.

Often misclassified as nonpharmacologic, sucrose is widely utilized in clinical practice despite outstanding questions regarding mechanism, efficacy, and long-term impact in preterm infants.\textsuperscript{53} Sucrose alters the behavioral response to painful stimuli by an unclear mechanism. Traditionally, stimulation of the endogenous opioid system was hypothesized, emphasizing the pharmacologic nature of sucrose. In rodents, ingestion of sucrose produces \( \beta \)-endorphin release in the hypothalamus, an effect blunted by opioid receptor antagonists.\textsuperscript{54,55} However, neither property has been replicated in human subjects.\textsuperscript{56,57} Mediation of dopaminergic, cholinergic, or serotonergic pathways have been proposed as potential alternative mechanisms of oral sucrose, although the role of these pathways has not been confirmed in preterm infants.\textsuperscript{58–60}

Clinical trials document reduction of crying, facial grimacing, and motor activity after oral administration of sucrose prior to minor painful procedures. The effective dose varies substantially in trials (range, 0.05–3 mL of 12–50% sucrose), although a recent randomized trial suggests 0.1 mL of 24% solution reduces the behavioral response to heel lance as effectively as higher doses.\textsuperscript{61} Despite significant influence on pain scores during skin-breaking procedures, oral sucrose does not consistently impact objective physiologic measures of pain. Specifically, oral sucrose does not decrease oxygen consumption or energy expenditure, has no impact on salivary or plasma cortisol concentrations, and has no effect on the neural activity of nociception-evoked circuits in the spinal cord or brain.\textsuperscript{53,62,63} Most strikingly, sucrose does not prevent the development of remote hyperalgesia in infants.\textsuperscript{64}

The limited understanding of the mechanism and objective efficacy of oral sucrose should promote great caution regarding long-term neurodevelopmental outcomes of preterm infants exposed repeatedly in the early stages of brain development. The true mechanism of action of oral sucrose clearly impacts the potential for adverse neurologic impact. Data regarding chronic opioid receptor stimulation clearly suggest the potential for negative neurologic impact.\textsuperscript{65} Dopamine, acetylcholine, and serotonin play central roles in development of motor function and attention, which is noteworthy considering the context of the available data regarding the developmental impact of sucrose. Repeated exposure to sucrose in the first week of life (ten times daily) prior to handling or needle prick as compared to placebo results in long-term alterations in white and gray matter volumes in mice.\textsuperscript{66} Mice that received sucrose prior to handling had poorer short-term memory in adulthood compared to controls, while the combination of sucrose and needle prick did not protect against impairment in short-term memory associated with repetitive pain.\textsuperscript{17} In human preterm infants, sucrose (0.1 mL of 24% solution) for all invasive procedures in the first week of life had no impact on measures of motor development or attention/orientation at term-equivalent follow-up in a single randomized controlled trial.\textsuperscript{37} However, increased sucrose exposure (greater than ten doses per day) was associated with poorer motor development and attention/orientation scores, an association not observed in the placebo group, suggesting this finding was not attributable to increased painful procedures.\textsuperscript{67,68} Additionally, a retrospective study found no protective effect from glucose prior to painful procedures on brain growth, functional connectivity, and neurodevelopmental impairments at 18 months of age.\textsuperscript{23} In this setting, randomized controlled trials of sucrose in preterm infants continue to be required, specifically examining short-term objective markers of efficacy and long-term neurodevelopmental effects.

PHARMACOTHERAPY FOR ANALGESIA AND SEDATION

Analogic and sedative practices vary considerably among hospitals, even for infants with similar characteristics, illness severity, and procedure burden.\textsuperscript{69,70} Provision of appropriate analgesia prior to invasive procedures prevents acute pain and clearly benefits the infant.\textsuperscript{11} Appropriate anesthesia prior to major surgery decreases postoperative physiologic instability and the incidence of acute brain injury.\textsuperscript{71} However, the optimal level of anesthesia and specific pharmacologic approach remains an area of highly active investigation beyond the scope of this review.\textsuperscript{14} Pre-medication prior to non-emergent endotracheal intubation significantly decreases the time and number of attempts needed to complete the procedure and minimizes the risk of airway trauma.\textsuperscript{71} However, investigation of the safety and efficacy of novel regimens utilized commonly in clinical practice should be prioritized.\textsuperscript{15}

The role of sedation or analgesia delivered by continuous infusion has not been clarified for infants who require invasive mechanical ventilation, despite extensive investigation (Table 2). Currently, consensus exists that continuous analgesic or sedative medications should be avoided when the duration of mechanical ventilation is expected to be short.\textsuperscript{72} Continuous analgesia and sedation are indicated when the infant’s physiology demands strict ventilator synchrony and minimization of oxygen consumption.\textsuperscript{72} However, in preterm infants requiring prolonged mechanical ventilation with comfort scale scores indicating the need for sedation approaches vary dramatically.\textsuperscript{18}

Benzodiazepines, most commonly midazolam, bind to the \( \gamma \)-aminobutyric acid (GABA\(_\text{A}\)) receptor complex, increasing the action of this inhibitory ion channel and resulting in sedation and anxiolysis. Clinical trials of continuous infusion midazolam therapy in preterm infants for sedation during mechanical ventilation have produced negative results. The pilot Neonatal Outcome and Prolonged Analgesia in Neonates (NOPAIN) trial documented an increase in severe IVH, periventricular leukomalacia, or death in infants randomized to midazolam therapy.\textsuperscript{73} This finding was most likely driven by hypotension associated with bolus doses of midazolam, and the associated persistent decrease in mean cerebral blood flow velocity.\textsuperscript{74} Long-term outcome data from preterm infants treated with continuous midazolam are not available. However, numerous preclinical studies have noted neuroapoptosis as well as long-term functional deficits and atypical behavioral patterns associated with benzodiazepines.\textsuperscript{65} Hence, both acute and long-term neurologic complications limit the utility of benzodiazepines in preterm infants.

Opioids bind \( \Gamma \) protein-coupled mu opioid receptors, producing analgesia and sedation through inhibition of ascending pathways in the brain stem, inhibition of neuronal firing in the dorsal horn of the spinal cord, and depression of both presynaptic and postsynaptic neuronal membrane potentials peripherally. Clinical trials of opioid therapy for sedation during mechanical ventilation have produced mixed results. Despite the promising results of the NOPAIN trial with regard to morphine, the NEOPAIN trial failed to document benefit with regard to acute brain injury.\textsuperscript{73,75} In addition, clear acute adverse effects occurred in infants randomized to morphine, including prolongation of the duration of mechanical ventilation, delayed tolerance of enteral feedings, and subtle tone abnormalities at 36 weeks postmenstrual age.\textsuperscript{76–78} Long-term follow-up of infants enrolled in the NEOPAIN trial was limited;\textsuperscript{79} however, robust follow-up of the European morphine trial revealed conflicting results with regard to neurodevelopment, with some detriment suggested at 5 years (lower scores on the
The influence of pain, agitation, and their management on the immature...  
C McPherson et al.

Table 2. Advantages and disadvantages of available agents for sedation of preterm neonates during mechanical ventilation.

| Agent          | Advantages                                      | Disadvantages                                      |
|----------------|-------------------------------------------------|----------------------------------------------------|
| Morphine       | Increased ventilator synchrony                  | Tachypnoea                                          |
|                | Decreased adrenaline concentrations             | Hypotension                                         |
|                | No impact on incidence of severe IVH, PVL, or death | Prolongation of mechanical ventilation              |
|                |                                                  | Reduced cerebellar growth at high doses             |
| Fentanyl       | Decreased adrenaline and cortisol concentrations | Rapid tachypnoea                                     |
|                | Less impact on gastrointestinal motility compared to morphine | Prolongation of mechanical ventilation              |
|                |                                                  | Delayed meconium passage                            |
| Midazolam      | Decreased sedation scores                       | Increased severe IVH, PVL, or death                 |
|                |                                                  | Hypotension                                         |
|                |                                                  | Myoclonus                                           |
|                |                                                  | Potential for neuroapoptosis and delayed motor      |
|                |                                                  | development                                         |
| Dexmedetomidine| Decreased adjunctive sedation compared to fentanyl | Potential hypotension                              |
|                | Decreased incidence of delirium compared to benzodiazepline |                                          |
|                | Minimal respiratory depression                   |                                                   |
|                | Minimal impact on gastrointestinal motility      |                                                   |
|                | Potential for neuroprotection after PVL, hypoxia-ischemia, or concurrent neurotoxic drug exposure |                  |

Table 2. Advantages and disadvantages of available agents for sedation of preterm neonates during mechanical ventilation.

| Agent          | Advantages                                      | Disadvantages                                      |
|----------------|-------------------------------------------------|----------------------------------------------------|
| Morphine       | Increased ventilator synchrony                  | Tachypnoea                                          |
|                | Decreased adrenaline concentrations             | Hypotension                                         |
|                | No impact on incidence of severe IVH, PVL, or death | Prolongation of mechanical ventilation              |
|                |                                                  | Reduced cerebellar growth at high doses             |
| Fentanyl       | Decreased adrenaline and cortisol concentrations | Rapid tachypnoea                                     |
|                | Less impact on gastrointestinal motility compared to morphine | Prolongation of mechanical ventilation              |
| Midazolam      | Decreased sedation scores                       | Increased severe IVH, PVL, or death                 |
|                |                                                  | Hypotension                                         |
|                |                                                  | Myoclonus                                           |
|                |                                                  | Potential for neuroapoptosis and delayed motor      |
|                |                                                  | development                                         |
| Dexmedetomidine| Decreased adjunctive sedation compared to fentanyl | Potential hypotension                              |
|                | Decreased incidence of delirium compared to benzodiazepline |                                          |
|                | Minimal respiratory depression                   |                                                   |
|                | Minimal impact on gastrointestinal motility      |                                                   |
|                | Potential for neuroprotection after PVL, hypoxia-ischemia, or concurrent neurotoxic drug exposure |                  |

visual analysis domain of intelligence quotient), but potential subtle benefits of randomization to morphine at 8–9 years of age (superior executive functions as assessed by parent report, although no difference by teacher report or standardized assessment by the study team).80–82

The long-term outcomes of children in the European morphine trial must be interpreted in the context of the morphine dosing utilized in the trial (100 μg/kg bolus, followed by 10 μg/kg/h for 7 days or less; median duration of invasive mechanical ventilation in the treatment group was 77 h). A retrospective study of children with similarly low-level morphine exposure during neonatal intensive care (median cumulative dose = 0.79 mg/kg) documents correlations between morphine exposure and brain morphology and behavioral dysregulation in infancy, but no correlation with cognitive or motor outcome at 2 years of age, or with brain morphology or developmental outcome at 7 years of age.83 In contrast, a retrospective study with higher-level exposure (median cumulative dose = 1.905 mg/kg) noted a strong correlation between morphine exposure and reduced cerebellar volume, poorer cognitive and motor outcomes, and behavioral problems in infancy.22,84 Interestingly, genetic variability impacting the metabolism of morphine modulates the association between exposure and behavioral problems in this cohort.84

Data regarding a pharmacokinetically different opioid emphasizes the importance of considering the degree of exposure when evaluating the potential long-term implications of therapy. Historic data suggest substantial accumulation of fentanyl in preterm infants treated with dosing commonly utilized in clinical practice, even after a robust loading dose.85 A randomized controlled trial suggests both acute and long-term adverse effects from fentanyl infusion, including prolonged duration of mechanical ventilation and an association with neurodevelopmental adverse effects at 24 months corrected age.86,87 A retrospective cohort study adds to concern, associating increased cumulative fentanyl exposure with reduced cerebellar growth at term-equivalent age.88 Importantly, a recent, robust pharmacokinetic study suggests potentially more appropriate doses of fentanyl as continuous infusion in young, preterm infants.89 This approach has the potential to mitigate some of the adverse effects of fentanyl; however, some degree of acute and long-term adverse effects appear to be inherent to exposure to any continuous infusion opioid in preterm infants.

α2-receptor agonists currently represent an interesting prospect to address the sedation needs of chronically mechanically ventilated preterm infants while minimizing both short- and long-term adverse effects. Dexmedetomidine is a highly selective α2-adrenergic receptor agonist that provides analgesia, anxiolysis, and sedation via reduction in sympathetic outflow from the locus coeruleus and release of substance P from the dorsal horn of the spinal cord. Clinical data in preterm infants are limited, but suggest the potential for short-term benefits compared to opioids, given the lack of respiratory depression and lack of impact on gastrointestinal motility.90,91 In contrast to benzodiazepines and opioids, preclinical data examining α2-agonists suggests neuroprotection of the immature brain.92 Extensive clinical research is required to define optimal dosing of dexmedetomidine in preterm infants and to clarify the safety and efficacy profile of this agent.

CLINICAL APPROACH TO PAIN AND AGITATION IN PRETERM INFANTS

Judicious utilization of laboratory assessments and procedures is a fundamental component of neonatal intensive care. Pain should be avoided and, when encountered, treated with a stepwise algorithm, including standardized nonpharmacologic and pharmacologic interventions. A systematic scoring system should be utilized prior to, during, and following acute painful procedures for all infants requiring neonatal intensive care in addition to regular scoring at care times. Standardized training for scoring and guidelines on the management of the score with regard to interventions for comfort should be developed by each NICU. Nonpharmacologic interventions, such as facilitated tucking, should be consistently utilized prior to mild to moderately painful procedures. If sucrose is utilized to mitigate behavioral responses to minor painful procedures, clinicians should administer the lowest effective dose less than ten times every 24 h in conjunction with
nonpharmacologic interventions. Anesthesia should be provided to prevent intraoperative pain and stress responses from major surgery. Rapidly acting opioid agents with a relatively short duration of action (fentanyl or remifentanil) should be provided prior to moderate painful procedures, including intubations.

Stress should be minimized during invasive mechanical ventilation by providing appropriate containment of the infant and an optimal sensory environment, including appropriate levels of light, noise, and maximal parent presence. Currently, no pharmacologic therapy has demonstrated safety and effectiveness for preterm infants requiring prolonged, invasive mechanical ventilation. Low-dose morphine (≤10 μg/kg/h and/or ≤50 μg/kg/dose as needed at least 5 min prior to agitating stimuli) may be utilized selectively on the basis of clinical judgment. Morphine may be titrated cautiously on the basis of pain scale scores and/or physiologic indicators of discomfort, carefully considering both short- and long-term risk/benefit ratio. In the setting of insufficient sedation from morphine, dexmedetomidine infusion may be considered, titrated carefully to effect while monitoring closely for adverse reactions.

FUTURE AREAS OF INVESTIGATION
Quantifying the impact of pain on brain development is complex. Given that severity of illness can be associated with increased need for painful interventions, it can be difficult to resolve the contribution of pain itself from the comorbid conditions resulting in painful stimuli. The subjective nature of most clinical pain assessment tools introduce a source of variability into comparative studies aimed to address pain in the newborn. Additionally, the known direct and indirect adverse pharmacological effects of sedative and analgesic medications on neuronal injury must be weighed against the clear adverse effects of untreated pain and agitation on the developing brain. Future research directions must address these three critical areas using a combination of preclinical models and pragmatic clinical studies. Development of objective measures of pain will need to interrogate physiological signals/responses to pain. Such tools would enable comparative studies of nonpharmacologic therapies and surcoce, which must also evaluate the long-term neurodevelopmental effects of these interventions. Rigorous clinical studies utilizing short- and long-term objective makers of safety and efficacy are also vital to address optimal dose, timing, and cumulative exposure to pharmacological agents. Anesthesia/analgesia is clearly indicated and clearly improves outcomes in the setting of major acute painful stimuli, although uncertainty about the optimal approach remains a source of variability in clinical practice and requires further investigation. The approach to preterm infants requiring long-term sedation/analgesia for mechanical ventilation is equally unclear, with major adverse effects inextricably linked to high-level exposure to both benzodiazepines and opioids. The potential promising role of dexmedetomidine in this population warrants careful investigation.

AUTHOR CONTRIBUTIONS
C.M., T.E.I. and S.P.M. drafted sections of the article. M.E-D. and A.N.M. revised it critically, contributing important intellectual content to the final manuscript. All authors provided final approval of the version to be published.

ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Symmes, A. R. et al. School entry age outcomes for infants with birth weight \(<\)
800 grams. J. Pediatr. 157, 989–994 (2010).
2. Schmidt, B. et al. Prediction of late death or disability at age 5 years using a count
of 3 neonatal morbidities in very low birth weight infants. J. Pediatr. 157, 982–986
(2015).
3. Synnes, A. et al. Determinants of developmental outcomes in a very preterm
cohort. Arch. Dis. Child. Fetal Neonatal Ed. 102, F235–F234 (2017).
4. Guo, T. et al. Quantitative assessment of white matter injury in preterm neonates:
association with outcomes. Neurology 88, 614–622 (2017).
5. Back, S. A. & Miller, S. P. Brain injury in premature neonates: a primary cerebral
dysmaturation disorder? Ann. Neurol. 75, 469–486 (2014).
6. Anand, K. Clinical importance of pain and stress in preterm neonates. Biol.
Neonate 73, 1–9 (1998).
7. Anand, K. J. & Craig, K. D. New perspectives on the definition of pain. Pain 67, 3–6
(1996). discussion 209–211.
8. Anand, K. J. & Hickey, P. R. Pain and its effects in the human neonate and fetus. N.
Engl. J. Med. 317, 1321–1329 (1987).
9. Anand, K. J., Sippell, W. G. & Aynsley-Green, A. Randomised trial of fentanyl
anaesthesia in preterm babies undergoing surgery: effects on the stress
response. Lancet 1, 62–66 (1987).
10. Fitzgerald, M., Shaw, A. & MacIntosh, N. Postnatal development of the cutaneous
flexor reflex: comparative study of preterm infants and newborn rats pups. Dev.
Med. Child Neonol. 30, 520–526 (1988).
11. Anand, K. J. Neonatal stress responses to anesthesia and surgery. Clin. Perinatol.
17, 207–214 (1990).
12. Fitzgerald, M., Millard, C. & McIntosh, N. Cutaneous hypersensitivity following
peripheral tissue damage in newborn infants and its reversal with topical
anaesthesia. Pain 39, 31–36 (1989).
13. Committee on Fetus and Newborn & Section on Anesthesiology and Pain
Medicine. Prevention and management of procedural pain in the neonate: an
update. Pediatrics 137, e20154271 (2016).
14. Dima, N. et al. Anesthesia and the developing brain: a way forward for laboratory
and clinical research. Paediatr. Anaesth. 28, 758–763 (2018).
15. Durrmeyer, X. et al. Premedication for neonatal endotracheal intubation: results
from the epidemiology of procedural pain in neonates study. Pediatr. Crit. Care
Med. 14, e169–e175 (2013).
16. Hatfield, L. A., Murphy, N., Karp, K. & Polemamo, R. C. A systematic review of
behavioral and environmental interventions for procedural pain management in
preterm infants. J. Pediatr. Nurs. 44, 22–30 (2019).
17. Ranger, M. et al. Adverse behavioral changes in adult mice following neonatal
repeated exposure to pain and sucrose. Front. Psychol. 9, 2394
(2018).
18. Zimmerman, K. O. et al. Sedation, analgesia, and paralysis during mechanical
ventilation of premature infants. J. Pediatr. 180, 99–104 (2017).
19. Miller, S. P. & Ferriero, D. M. From selective vulnerability to connectivity: insights
from newborn brain imaging. Trends Neurosci. 32, 496–505 (2009).
20. Woodward, L. J., Anderson, P. J., Austin, N. C., Howard, K. & Inder, T. E. Neonatal
MRI to predict neurodevelopmental outcomes in preterm infants. N. Engl. J. Med.
355, 685–694 (2006).
21. Buser, J. R. et al. Arrested preoligodendrocyte maturation contributes to myeli-
ation failure in premature infants. Ann. Neurol. 71, 93–109 (2012).
22. Zwicker, J. G. et al. Smaller cerebellar growth and poorer neurodevelopmental
outcome in preterm infants. Ann. Neurol. 68, 462–465 (2008).
23. Toulin, H. et al. Specialization and integration of functional thalamocortical
connectivity in the human infant. Proc. Natl Acad. Sci. USA 112, 6485–6490
(2015).
24. Duerden, E. G. et al. Midazolam dose correlates with abnormal hippocampal
growth and neurodevelopmental outcome in preterm infants. Ann. Neurol. 79,
548–559 (2016).
25. Duerden, E. G. et al. Early procedural pain is associated with regionally-specific
alterations in thalamic development in preterm neonates. J. Neurosci. 38,
878–886 (2018).
26. Netz, O. K. et al. Neonate hippocampal volumes: prematurity, perinatal
predictors, and 2-year outcome. Ann. Neurol. 71, 385–396 (2012).
27. Toulmin, H. et al. Specialization and integration of functional thalamocortical
connectivity in the human infant. Proc. Natl Acad. Sci. USA 112, 6485–6490
(2015).
28. Brummelte, S. et al. Procedural pain and brain development in premature new-
borns. Ann. Neurol. 71, 385–396 (2012).
29. Zwicker, J. G. et al. Score for neonatal acute physiology-II and neonatal pain
predict corticospinal tract development in premature newborns. Pediatr. Neurol.
48, 123–129 (2013).
30. Smith, M. et al. Neonatal intensive care unit stress is associated with brain
development in preterm infants. Ann. Neurol. 70, 541–549 (2011).
31. Ranger, M. et al. Neonatal pain-related stress predicts cortical thickness at age 7 years in children born very preterm. PLoS ONE 8, e76702 (2013).
32. Chau, C. M. Y. et al. Hippocampus, amygdala, and thalamus volumes in very preterm children at 8 years: neonatal pain and genetic variation. Front. Behav. Neurosci. 13, 51 (2019).
33. Vinall, J. et al. Invasive procedures in preterm children: brain and cognitive development at age 7. Pediatrics 133, 412–421 (2014).
34. Doesburg, S. M. et al. Neonatal pain-related stress, functional cortical activity and visual–perceptual abilities in school-age children born at extremely low gestational age. Pain 154, 1946–1952 (2013).
35. Blass, E., Fitzgerald, E. & Kehoe, P. Interactions between sucrose, pain and isolation-induced stress in neonates: a randomised controlled trial. BMC Pediatr. 18, 85 (2018).
36. Roue, J. M. et al. Multi-modal pain assessment: are near-infrared spectroscopy, skin conductance, salivary cortisol, physiologic parameters, and Neonatal Facial Coding System Revised: Training Manual (University of British Columbia, Vancouver, 2010).
37. Bordini, E. C. et al. Repeated exposure to sucrose for procedural pain in mouse pups leads to long-term widespread brain alterations. Pain 158, 1586–1598 (2017).
38. Johnston, C. C. et al. Routine sucrose analgesia during the first week of life in neonates younger than 31 weeks’ postconceptional age. Pediatrics 110, 523–528 (2002).
39. Jones, P. G. & Dunlop, J. Targeting the cholinergic system as a therapeutic strategy for the treatment of pain. Neuropharmacology 53, 197–206 (2007).
40. Reboucas, E. C. et al. Effect of the blockade of mu1-opioid and 5HT2A-serotoninergic/alpha1-noradrenergic receptors on sweet-substance-induced analgesia. Psychopharmacology 179, 349–355 (2005).
41. Smitherman, A. J. et al. The influence of pain, agitation, and their management on the immature. J. Pediatr. 136, 767–770 (2000).
42. McPherson, C. & Grunau, R. E. Neonatal pain control and neurologic effects of sedative drugs in the NICU: integrating clinical trials and laboratory data. Pediatr. Res. 67, 117–127 (2010).
43. Lang, J. E. et al. Premature infant pain profile-revised (PIPP-R). Early Hum. Dev. 90, 189–193 (2014).
44. Lawrence, J. et al. Clinical reliability and validity of the N-PASS: neonatal pain, agitation and sedation scale with prolonged sedation. J. Perinatol. 28, 55–60 (2008).
45. Lawrence, J. et al. The development of a tool to assess neonatal pain. Neonatal Netw. 12, 59–66 (1993).
46. Cognacce, E., Mueller, R., Hamers, J. P. & Gessler, P. Pain assessment in the neonate using the Bernese Pain Scale for Neonates. Early Hum. Dev. 78, 125–131 (2004).
47. Kappesser, J. et al. Pain-specific reactions or indicators of a general stress response? Investigating the discriminant validity of 5 well-established neonatal pain assessment tools. Clin. J. Pain 35, 101–110 (2019).
48. Benoit, B., Martin-Misener, R., Newman, A., Latimer, M. & Campbell-Yeo, M. Neurophysiological assessment of acute pain in infants: a scoping review of research methods. Acta Paediatr. 106, 1053–1066 (2017).
49. Fabricz, L. et al. A shift in sensory processing that enables the developing human brain to discriminate touch from pain. Curr. Biol. 21, 1552–1558 (2011).
50. Slater, R. et al. Premature infants display increased noxious-activated neuropeptide activity in the brain compared to healthy age-matched term-born infants. Neuroimage 52, 583–589 (2010).
51. Distel, N. L., Lamerizet, D. G., & Anand, K. J. Pain activates cortical areas in the preterm newborn brain. Pain 122, 109–117 (2006).
52. Munsters, J., Wallstrom, L., Agren, J., Norsted, T. & Sindelar, R. Skin conductance measurements as pain assessment in newborn infants born at 22–27 weeks gestational age at different postnatal age. Early Hum. Dev. 88, 21–26 (2012).
53. Jansen, J., Beijers, R., Risken-Walraven, M. & de Weerth, C. Cortisol reactivity in young infants. Psychoneuroendocrinology 35, 329–338 (2010).
54. Roue, J. M. et al. Multi-modal pain assessment: near-infrared spectroscopy, skin conductance, salivary cortisol, physiologic parameters, and Neonatal Facial Coding System Interrelated during venepuncture in healthy, term neonates. J. Pain Res. 11, 2257–2267 (2018).
55. Pena-Bautista, C. et al. Non-invasive monitoring of stress biomarkers in the newborn period. Semin. Fetal Neonatal Med. 24, 101002 (2019).
56. Pillai Riddell, R. R. et al. Non-pharmacological management of infant and young child procedural pain. Cochrane Database Syst. Rev. CD006275 (2015).
57. Carbajal, R. et al. Neonatal pain management: some progress towards standardization. Arch. Pediatr. Adolesc. Med. 168, ra8 (2013).
58. Grunau, R. E. et al. Neonatal analgesia and sedation during and after surgery in neonates: a randomised controlled trial. Lancet 376, 1225–1232 (2010).
59. Taddio, A., Shah, V., Atanadu, E. & Katz, J. Influence of repeated painful procedures and sucrose analgesia on the development of hyperalgesia in newborn infants. Pain 144, 43–48 (2009).
60. Durrmeyer, X., Vutsikis, L., Anand, K. J. & Rimensberger, P. C. Use of analgesic and sedative drugs in the NICU: integrating clinical trials and laboratory data. Pediatr. Res. 67, 117–127 (2010).
61. McPherson, C. & Grunau, R. E. Neonatal pain control and neurologic effects of sedative drugs in the NICU: integrating clinical trials and laboratory data. Pediatr. Res. 67, 608–615 (2010).
62. Ancora, G. et al. Evidence-based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. Acta Paediatr. 108, 208–217 (2019).
63. Anand, K. J. et al. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. Neonatal Outcome and Prolonged Analgesia in Neonates. Arch. Pediatr. Adolesc. Med. 153, 331–338 (1999).
64. van Straaten, H. L., Rademaker, C. M. & de Vries, L. S. Comparison of the effect of midazolam or vecuronium on blood pressure and cerebral blood flow velocity in the premature newborn. Dev. Pharmacol. Ther. 19, 191–195 (1992).
65. Anand, K. J. et al. Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial. Lancet 363, 1673–1682 (2004).
66. Bhandari, V., Bergqvist, L. L., Kronsberg, S. S., Barton, B. A. & Anand, K. J. Morphine administration and short-term pulmonary outcomes among ventilated preterm infants. Pediatrics 116, 352–359 (2005).
67. Menon, G. et al. Morphine analgesia and gastrointestinal morbidity in preterm infants: secondary results from the NEOPAIN trial. Arch. Dis. Child Fetal Neonatal Ed. 93, F362–F367 (2008).
68. Rao, R. et al. Neurobehavior of preterm infants at 36 weeks postconception as a function of morphine analgesia. Am. J. Perinatol. 24, 511–517 (2007).
69. Ferguson, S. A., Ward, L. W., Paule, M. G., Hall, R. W. & Anand, K. J. A pilot study of preemptive morphine analgesia in preterm neonates: effects on head circumference, social behavior, and response latencies in early childhood. Neurotoxicol. Teratol. 34, 47–55 (2012).
70. Simons, S. H. et al. Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial. J. Am. Med. Assoc. 290, 2419–2427 (2003).
71. de Graaf, J. et al. Long-term effects of routine morphine infusion in mechanically ventilated neonates on children's functioning: five-year follow-up of a randomized controlled trial. Pain 152, 1391–1397 (2011).
72. de Graaf, J. et al. Does neonatal morphine use affect neuropsychological outcomes at 8 to 9 years of age? Pain 154, 449–458 (2013).
73. Steinhorn, R. et al. Neonatal morphine exposure in very preterm infants—cerebral development and outcomes. J. Pediatr. 166, 1200–1207 (2015). e1204.
74. Cau, M. Y. et al. Morphine biotransformation genes and neonatal clinical factors predicted behavior problems in very preterm children at 18 months. Ebiologia 40, 655–662 (2019).
75. Saaremets, E., Neuvonen, P. J. & Fellman, V. Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J. Pediatr. 136, 767–770 (2000).
86. Ancora, G. et al. Efficacy and safety of continuous infusion of fentanyl for pain control in preterm newborns on mechanical ventilation. *J. Pediatr.* **163**, 645–651 (2013). e641.

87. Ancora, G. et al. Follow-up at the corrected age of 24 months of preterm newborns receiving continuous infusion of fentanyl for pain control during mechanical ventilation. *Pain* **158**, 840–845 (2017).

88. McPherson, C. et al. Brain injury and development in preterm infants exposed to fentanyl. *Ann. Pharmacother.* **49**, 1291–1297 (2015).

89. Völker, S. et al. Rapidly maturing fentanyl clearance in preterm neonates. *Arch. Dis. Child-Fetal Neonatal Ed.* [https://doi.org/10.1136/archdischild-2018-315920](https://doi.org/10.1136/archdischild-2018-315920) (2019).

90. O’Mara, K. et al. Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. *J. Pediatr. Pharm. Ther.* **17**, 252–262 (2012).

91. Chrysostomou, C. et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. *J. Pediatr.* **164**, 276–282 (2014). e271-273.

92. Laudenbach, V. et al. Effects of alpha2-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. *Anesthesiology* **96**, 134–141 (2002).